{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:15:15Z","timestamp":1790943315182,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"publisher","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope on Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2025.03.019","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:16:35Z","timestamp":1741900595000},"page":"3360-3374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-290X","authenticated-orcid":false,"given":"Alexandra","family":"Dreyzin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Lee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Prochazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongye","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Highfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorkell","family":"Andresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.019_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.019_bib2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178403","article-title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","volume":"14","author":"Fergusson","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib7","first-page":"73.e1","article-title":"Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transpl. Cel. Ther."},{"key":"10.1016\/j.ymthe.2025.03.019_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj2820","article-title":"Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL","volume":"8","author":"Bai","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.03.019_bib9","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.3390\/cancers13174279","article-title":"Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy","volume":"13","author":"Lamure","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.019_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.019_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood-2019-122513","article-title":"Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.019_bib12","article-title":"The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma","volume":"13","author":"Worel","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib13","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.019_bib14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/cells11071140","article-title":"Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies","volume":"11","author":"Beider","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.019_bib15","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.019_bib16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.019_bib17","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.019_bib18","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.019_bib19","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.4049\/jimmunol.0904084","article-title":"Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses","volume":"184","author":"Hoelzinger","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S439969","article-title":"CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer","volume":"13","author":"Li","year":"2024","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.ymthe.2025.03.019_bib22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.019_bib23","first-page":"3153","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.019_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.smim.2012.04.010","article-title":"IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis","volume":"24","author":"Carrette","year":"2012","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib25","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.4049\/jimmunol.179.11.7448","article-title":"Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue","volume":"179","author":"Lim","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib26","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","article-title":"GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency","volume":"15","author":"Guerrero","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.019_bib27","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.4049\/jimmunol.174.5.2900","article-title":"Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals","volume":"174","author":"Paiardini","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib28","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.4049\/jimmunol.180.8.5582","article-title":"CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection","volume":"180","author":"Dunham","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s42003-024-06297-0","article-title":"A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism","volume":"7","author":"Takayanagi","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer. Cell."},{"key":"10.1016\/j.ymthe.2025.03.019_bib32","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.019_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101249","article-title":"Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence","volume":"32","author":"Cappabianca","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.019_bib34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/bloodadvances.2023010607","article-title":"Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.019_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","article-title":"CAR-T cell expansion platforms yield distinct T cell differentiation states","volume":"26","author":"Song","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2025.03.019_bib36","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.019_bib37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2025.03.019_bib39","first-page":"438.e1","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl. Cel. Ther."},{"key":"10.1016\/j.ymthe.2025.03.019_bib40","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry. A."},{"key":"10.1016\/j.ymthe.2025.03.019_bib41","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.03.019_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.03.019_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC. Bioinformatics."},{"key":"10.1016\/j.ymthe.2025.03.019_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.019_bib45","doi-asserted-by":"crossref","first-page":"W415","DOI":"10.1093\/nar\/gkae456","article-title":"WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics","volume":"52","author":"Elizarraras","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.019_bib46","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","article-title":"The Reactome Pathway Knowledgebase 2024","volume":"52","author":"Milacic","year":"2024","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:14:41Z","timestamp":1782958481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001625001935"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}